Welcome to our dedicated page for The Beauty Health Company SEC filings (Ticker: SKIN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Beauty Health Company (NASDAQ: SKIN) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a medtech meets beauty business in skin health and aesthetics. This page aggregates those SEC filings and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
Investors can use this resource to access current reports on Form 8-K, where BeautyHealth discloses material events such as quarterly financial results, leadership transitions, board appointments, debt and indenture changes, and amendments to its certificate of incorporation. For example, recent 8-K filings discuss the appointment of a new President and Chief Executive Officer, the appointment of a new independent director, a supplemental indenture related to 7.95% convertible senior notes due 2028, and a certificate of correction to its charter.
In addition to 8-Ks, the company’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) provide detail on net sales, gross margin, adjusted EBITDA, delivery systems sold, active install base, regional performance, risk factors, and capital structure. These filings outline how BeautyHealth combines delivery systems and consumables in its revenue model and how it reports non-GAAP measures alongside GAAP results.
This page also offers easy access to insider and equity-related filings, such as Forms 3, 4, and 5 when they are filed, which can show transactions by directors and officers, as well as proxy and governance documents that describe director compensation, board structure, and key agreements. AI-generated explanations help clarify complex sections, highlight important changes, and point out items that may matter most to shareholders, analysts, and anyone researching SKIN’s regulatory history.
Form 4 filing for The Beauty Health Company (SKIN) discloses that director Michelle C. Kerrick was granted 73,051 restricted stock units (RSUs) on 06/16/2025 (Transaction Code A).
• The RSUs vest on the earlier of the one-year anniversary of the grant or the date of the company’s 2026 annual shareholders’ meeting, subject to her continued board service.
• After the grant, Kerrick’s total beneficial ownership increases to 189,813 Class A shares, held directly.
• No derivative securities were involved and no shares were sold.
The filing represents routine director equity compensation and does not indicate any open-market buying or selling activity.
Beauty Health Company (ticker: SKIN) filed a Form 4 disclosing an insider equity grant. Director Brian Christopher Miller received 73,051 Class A common-stock RSUs on 16 June 2025. The award is classified as an acquisition (Code A) and is part of routine director compensation.
The RSUs will vest on the earlier of the one-year anniversary of the grant or the 2026 annual shareholder meeting, subject to Miller’s continued board service. Following the grant, Miller’s beneficial ownership increased to 243,035 shares, held directly. No derivative securities or sales were reported, and no 10b5-1 trading plan was indicated.
Beauty Health Company (SKIN) – Form 4 insider filing
Director Doug K. Schillinger reported the grant of 73,051 restricted stock units (RSUs) on 16 Jun 2025. The award is coded "A" (acquisition) and is part of the company’s director compensation program rather than an open-market purchase. Vesting occurs on the earlier of (i) the one-year anniversary of the grant or (ii) the 2026 annual shareholders’ meeting, subject to the director’s continued board service.
Following this grant, Schillinger’s total beneficial ownership increased to 216,035 Class A common shares, all held directly. No derivative securities were reported.
The filing signals continued equity-based alignment between the board and shareholders but does not, by itself, alter Beauty Health’s financial outlook or capital structure.